# Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections

> **NCT00426933** · PHASE2 · COMPLETED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 100 (actual)

## Conditions studied

- Soft Tissue Infections

## Interventions

- **DRUG:** Daptomycin
- **DRUG:** Vancomycin

## Key facts

- **NCT ID:** NCT00426933
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2010-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00426933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00426933, "Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00426933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*